期刊
VIRCHOWS ARCHIV
卷 477, 期 1, 页码 83-91出版社
SPRINGER
DOI: 10.1007/s00428-020-02751-6
关键词
PD-1; PD-L1 pathway; Tumor-infiltrating lymphocytes; Macrophages; Prognostic marker
类别
资金
- Lund University
- Swedish Cancer Society [2015/486]
- G Nilsson Cancer Foundation [2017/728]
- B Kamprad Foundation [FBKS 2017/22]
- Cancer and Allergy Foundation [2017/150428]
- King Gustaf V's Jubilee Foundation [2017/174161]
- Lund University Hospital Research Foundation [2017-033]
- National Health Services (ALF) [2014/10601]
- National Health Services
- BioCare
The response rate to checkpoint inhibitors for women with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum (HGSC) is modest, and development of predictive biomarkers is needed. The main focus has been on tumor cell PD-L1 expression, but its assessment alone is insufficient for patient selection in most malignancies. We mapped the presence of macrophages (CD68 and CD163) and lymphocytes (CD3) located within the tumor epithelium, the cell type-specific expression of PD-L1 and PD-1, and their impact on 5-year overall survival (OS) in a consecutive cohort of 130 women diagnosed with advanced HGSC between 2011 and 2015. PD-L1 was expressed mainly by macrophages (not by tumor cells) and PD-1 by lymphocytes. Women with higher CD3, PD-L1, and PD-1 expression had improved OS (P = 0.03, P = 0.007, and P = 0.02, respectively). In the external data set (203 women), high expression of CD274 (encoding PD-L1) was associated with improved OS (P = 0.03), in accordance with our results. Furthermore, higher CD163 expression was associated with better outcome in women with no residual tumor after primary surgery (P = 0.02). Thus, women with greater lymphocyte tumor infiltration had better outcome and PD-L1/PD-1 expression, regardless of PD-1/PD-L1 being markers for immune suppressive pathways, conferred a survival benefit in our cohort. Our results highlight that tumor immunity may be harnessed in subsets of HGSC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据